Shionogi & Co., Ltd. manufactures and distributes pharmaceuticals, diagnostic reagents, medical devices, etc. primarily in Asia, North America, and Europe. Its principal products include various prescription drugs, including Osphena to treat postmenopausal vulvar and vaginal atrophy; Crestor tablets for the treatment of hyperlipidemia; Irbetan tablets for the treatment of hypertension; Cymbalta capsules to treat depression, depressive condition, and diabetic neuropathic pain; cancer pain analgesics, such as OxyContin tablets, OxiNorm powders, and OxiFast injections; Tivicay tablets for HIV treatment; Finibax and Finibax solution kit for intravenous drip infusion; Differin gel for the treatment of topical acne vulgaris; Pirespa tablets used to treat idiopathic pulmonary fibrosis; and Rapiacta, an antiviral drug for the treatment of influenza. The company also offers over the counter drugs comprising Popon series of multiple vitamin supplements; and Sedes, a line of analgesic antipyretics. In addition, it provides diagnostics reagents, such as Shionospot Reader and Shionospot BNP, a human brain natriuretic peptide kit; Allerport TARC, a thymus and activation-regulated chemokine kit; Allerport HRT, a reagent for identifying allergens; Brightpoc Flu, an influenza virus diagnostic kit; and Checkart Reader for measuring hemoglobin A1c and glucose levels in blood for use in diagnosing diabetes and other related clinical conditions. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.